Tapering biologics in stable rheumatoid arthritis kept control in most patients

Design

Multicentre, randomised, open-label, non-inferiority trial, 24 weeks

Population

348 adults with RA in sustained low disease activity on b/tsDMARDs, Korea

Primary outcome

Maintenance of DAS28-ESR low disease activity at week 24

Effect

88.2% vs 89.6%; risk difference -1.43% (-8.09 to 5.23)

This 24-week, multicentre, open-label, non-inferiority trial in Korea randomised 348 patients with rheumatoid arthritis who had held DAS28-ESR low disease activity for at least six months on a stable biologic or targeted synthetic DMARD. Patients either continued the full dose or followed a stepwise taper.

Low disease activity was maintained in 88.2% of the tapering group and 89.6% of the continuation group (risk difference -1.43%, 95% CI -8.09 to 5.23), meeting the -10% non-inferiority margin. Most patients who worsened regained low disease activity after protocol-guided re-escalation. Some secondary measures favoured continuation, including DAS28-ESR and SDAI at 24 weeks. Adverse events were uncommon.

For Indian patients who pay for biologics and JAK inhibitors themselves, a structured taper in sustained low disease activity is a reasonable way to cut cost and exposure. Twenty-four weeks is short, and the open-label design and the secondary scores favouring continuation argue for close monitoring and a ready plan to step back up.

• Consider a stepwise taper after at least six months of sustained low disease activity on a biologic or JAK inhibitor.
• Agree in advance the flare criteria and the plan for re-escalation.
• Review disease activity at least every three months during tapering.
• Do not taper patients with recent flares, erosive progression or only borderline control.

Why it matters

Most patients stay on full-dose advanced therapy indefinitely, and this supports doing otherwise for selected patients.

Don't overread it

Only 24 weeks of follow-up in an open-label trial; longer-term flare and damage risk are not addressed.

The statistics, in plain English

Non-inferiority means tapering was not worse than continuation by more than 10 percentage points. The lower bound of the interval (-8.09%) stayed inside that margin, but a loss of control in up to 8 more patients per 100 cannot be excluded.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.